Polyionic Papilloma Virus-like Particle (VLP) Vaccines

Case ID:
Disclosure Date:
Value Proposition:
-Attractive vaccine candidates that are not infectious and have self-assembling properties.
-Vaccine particles can accommodate a wide range of antigens in terms of size and composition.
-Antigens may be loaded onto pre-formed vaccine particles without interfering with the self- assembling properties of the carrier.
-The present technology can elicit a strong cytotoxic T cell response in absence of adjuvant.
Technical Details:
JHU scientists have developed a generic platform technology for vaccines based on chimeric papillomavirus VLPs. The potential use of this technology in developing vaccines for cancer and infectious diseases (eg. malaria; dengue, and SARS). This technology may be further developed to have application in areas particularly where it is desirable to induce CD8 T cell responses.
Why we need T cell vaccines
Looking for Partners:
This technology may be developed as a vaccine for various conditions
Publications/Associated Cases:
Pejawar-Gaddy et al (2010) Generation of a Tumor Vaccine Candidate Based on Conjugation of a MUC1 Peptide to Polyionic Papillomavirus Virus-Like Particles (VLPs). Cancer Immunol Immunother. 59(11): 1685–1696
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Polyionic Papilloma Virus-like Particle (VLP) Vaccines CON: Continuation United States 16/214,211 12/10/2018     Pending
For Information, Contact:
Nakisha Holder
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum